Translations:Research/key-initiatives/ras/spokes-funding/12/en

From loveco.care
Revision as of 23:27, 29 October 2019 by FuzzyBot (talk | contribs) (Importing a new version from external source)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Charles Rudin, Memorial Sloan Kettering Cancer Center
 Charles Rudin, Memorial Sloan Kettering Cancer Center, for "Identification and Validation of Synthetic Lethality in KRAS Mutant Lung Adenocarcinoma Patient Derived Xenografts." Dr. Rudin and his team will modify patient-derived xenografts of human lung cancers harboring the most common mutant KRAS alleles to express Cas9, after which they will be selected and transduced with sgRNAs in vivo. DNAs from resulting tumors will be sequenced to determine which sgRNAs are underrepresented and thus indicate target genes that are essential for KRAS-dependent tumor formation.
Retrieved from "http://www.loveco.care/index.php?title=Translations:Research/key-initiatives/ras/spokes-funding/12/en&oldid=10499"